传染科

订阅

MedSci主页 / 所有栏目 / 传染科

SCIENCE: SARS-CoV-2开始是如何适应人类的

2021-04-30 MedSci原创 MedSci原创

SARS-COV-2D614G突变S蛋白
关注

病毒需要侵入蛋白来穿透细胞进行复制。SARS-CoV-2版本被称为刺突蛋白或S蛋白。S蛋白也是目前疫苗的目标，正在迅速适应新的人类宿主。

病毒需要侵入蛋白来穿透细胞进行复制。SARS-CoV-2版本被称为刺突蛋白或S蛋白。S蛋白也是目前疫苗的目标，正在迅速适应新的人类宿主。在2020年初，它在这个方向上迈出了重要的第一步，当时它的氨基酸614(1297个)从天冬氨酸(D)变成了甘氨酸(G)。携带这种D614G突变的病毒在人类中传播得更快，现在占大多数。Zhang等人通过仔细的结构分析揭示了D614G是如何改变S蛋白从而加速大流行的。 在SARS-CoV-2大流行的早期，在匆忙创建研究工具的过程中，研究人员开发了假病毒系统，以一种安全、容易量化的方式测量感染。这些系统在报告病毒表面表达一种病毒入侵蛋白，用于监测细胞入侵，多年来一直用于研究许多此类蛋白，包括“经典”SARS-CoV-1的S蛋白。令人沮丧的是，由SARS-CoV-2 S蛋白构建的假病毒比基于非常相似的SARS-CoV-1 S蛋白构建的假病毒产生的信号低得多。这令人困惑，因为对SARS-CoV-1和SARS-CoV-2 s蛋白受体结合域(RBD)的生化研究表明，SARS-CoV-2 RBD与它们共同的受体血管紧张素转换酶2 (ACE2)的结合比SARS-CoV-

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1938007, encodeId=752c193800e6f, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Aug 31 04:48:22 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321273, encodeId=2f2013212e3d0, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Sun May 02 11:48:22 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376290, encodeId=094813e629045, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun May 02 11:48:22 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962160, encodeId=08de96216012, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65d55484096, createdName=汉水人家, createdTime=Sat May 01 19:49:57 CST 2021, time=2021-05-01, status=1, ipAttribution=)]
    2021-08-31 hukaixun

    #SARS-CoV#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1938007, encodeId=752c193800e6f, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Aug 31 04:48:22 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321273, encodeId=2f2013212e3d0, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Sun May 02 11:48:22 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376290, encodeId=094813e629045, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun May 02 11:48:22 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962160, encodeId=08de96216012, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65d55484096, createdName=汉水人家, createdTime=Sat May 01 19:49:57 CST 2021, time=2021-05-01, status=1, ipAttribution=)]
    2021-05-02 小刀医生

    #SARS#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1938007, encodeId=752c193800e6f, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Aug 31 04:48:22 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321273, encodeId=2f2013212e3d0, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Sun May 02 11:48:22 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376290, encodeId=094813e629045, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun May 02 11:48:22 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962160, encodeId=08de96216012, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65d55484096, createdName=汉水人家, createdTime=Sat May 01 19:49:57 CST 2021, time=2021-05-01, status=1, ipAttribution=)]
    2021-05-02 jichang

    #SCIE#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1938007, encodeId=752c193800e6f, content=<a href='/topic/show?id=02de15902d3' target=_blank style='color:#2F92EE;'>#SARS-CoV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15902, encryptionId=02de15902d3, topicName=SARS-CoV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Tue Aug 31 04:48:22 CST 2021, time=2021-08-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1321273, encodeId=2f2013212e3d0, content=<a href='/topic/show?id=ac0d159007f' target=_blank style='color:#2F92EE;'>#SARS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15900, encryptionId=ac0d159007f, topicName=SARS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8306486, createdName=小刀医生, createdTime=Sun May 02 11:48:22 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1376290, encodeId=094813e629045, content=<a href='/topic/show?id=2949159989d' target=_blank style='color:#2F92EE;'>#SCIE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15998, encryptionId=2949159989d, topicName=SCIE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=17a3387, createdName=jichang, createdTime=Sun May 02 11:48:22 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=962160, encodeId=08de96216012, content=学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=65d55484096, createdName=汉水人家, createdTime=Sat May 01 19:49:57 CST 2021, time=2021-05-01, status=1, ipAttribution=)]
    2021-05-01 汉水人家

    学习学习

    0

相关资讯

Circulation：感染SARS-CoV-2的年轻运动员心脏受累情况

SARS-CoV-2感染的年轻运动员短期随访中心脏受累患病率和临床事件风险均较低。

BMJ：儿童SARS-CoV-2血清流行的聚集性和纵向变化——对55所学校的前瞻性队列研究

尽管SARS-CoV-2在社区中中度至高传播期间整体血清流行率有所上升，但随着2020年8月学校开学并采取了一些预防措施，只有少数班级出现了聚集性血清阳性儿童。

Science ：多数SARS-CoV-2变体很少通过次级传播而持续存在

Worldometers世界实时统计数据显示，全球累计确诊新冠肺炎（COVID-19）病例超过1亿2003万例，累计死亡病例超265.8万例。

Lancet Global Health：人类感染SARS-CoV-2的血清学证据汇总

现有的血清学证据表明，没有个人防护设备的密切接触者和医护人员感染的风险较高。在大多数环境下，人群免疫远未实现。

Cell：新冠疫苗任重道远：多种COVID-19变异株通过疫苗诱导的体液免疫逃避中和

重要的是开发能够防止各种SARS-CoV-2变种传播的干预措施，包括针对这些变种的疫苗增强剂，或者能够诱导或传递广泛中和抗体的技术。

如何应对SARS-CoV-2加州变种？VIR-7831具有中和活性

Vir生物技术公司今天宣布进行新的临床前研究，证明该公司的研究性SARS-CoV-2单克隆抗体VIR-7831能够保持其中和作用。